Format

Send to

Choose Destination
See comment in PubMed Commons below
Nephrol Ther. 2014 Jun;10(3):170-6. doi: 10.1016/j.nephro.2013.11.006. Epub 2014 Apr 3.

[Proliferative lupus nephritis treatment: practice survey in nephrology and internal medicine in France].

[Article in French]

Author information

1
Service de néphrologie, Aix-Marseille université, hôpital de la Conception, 147, boulevard Baille, 13385 Marseille cedex 5, France. Electronic address: noemie.jourde@ap-hm.fr.
2
Service de médecine interne, Aix-Marseille université, hôpital de la Conception, 147, boulevard Baille, 13385 Marseille cedex 5, France.
3
Service de santé publique, Aix-Marseille université, hôpital de la Timone, 264, rue Saint-Pierre, 13385 Marseille cedex 5, France.
4
Service d'anatomie pathologique, Aix-Marseille université, hôpital de la Timone, 264, rue Saint-Pierre, 13385 Marseille cedex 5, France.
5
Laboratoire d'immunologie, Aix-Marseille université, hôpital de la Conception, 147, boulevard Baille, 13385 Marseille cedex 5, France.
6
Service de néphrologie, Aix-Marseille université, hôpital de la Conception, 147, boulevard Baille, 13385 Marseille cedex 5, France.
7
Service de médecine interne, hôtel-Dieu, 1, place Alexis-Ricordeau, 44093 Nantes cedex 1, France.
8
Service de néphrologie, centre hospitalier Henri-Duffaut, 305, rue Raoul-Follereau, 84000 Avignon, France.
9
Service de néphrologie, hôpital Bichat, 46, rue Henri-Huchard, 75018 Paris, France.

Abstract

European and American recommendations have recently been published for the treatment of proliferative lupus nephritis (LN). This study aimed to describe current practice in France. An electronic survey was sent to French nephrologists and internists via their scientific society between March and December 2012. One hundred and nine specialists (60 internists, 48 nephrologists and 1 rheumatologist), mostly from hospitals, completed the survey. Low-dose cyclophosphamide (Euro-Lupus) was the first induction immunosuppressive therapy used (67%), followed by mycophenolate mofetil (MMF) (20%) and high dose CYC (NIH, 9%). Maintenance immunosuppressive therapy after an induction with CYC was preferentially MMF (58%), versus 14% for azathioprine (AZA) and 25% using either MMF or AZA without preference. After an induction with MMF, maintenance treatment was mainly MMF (77%). Antimalarial drugs were prescribed systematically by 86% of specialists. In patients in stable remission, maintenance treatment was withdrawn after 2 years (40%), 3 years (25%) or more (34%). Low-dose corticosteroids were continued in the long-term by 54% of specialists. No difference was observed between nephrologists and internists, even in the prescription of antimalarials. Treatment of proliferative LN in France is homogenous enough and is consistent with recent international recommendations.

KEYWORDS:

Enquête de pratique; Induction treatment lupus nephritis; Maintenance treatment; Néphropathie lupique; Survey; Traitement d’entretien; Traitement d’induction

PMID:
24703567
DOI:
10.1016/j.nephro.2013.11.006
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center